Menu
Job Title
Senior Research Assistant
Academic Rank
Staff/Research Assistant
Department
Neurology
Authors
Steven Cicero, Steven Vaquerano, Bonnie Glanz, Shipra Dubey, Renxin Chu, Rohit Bakshi, Tarun Singhal
Principal Investigator
Tarun Singhal
Categories
Tags
Cortical grey (CoGM) and white matter (WM) microglial activation (MA) is involved in the pathogenesis of multiple sclerosis (MS). [F-18]PBR06 positron emission tomography (PET) targeting translocator protein (TSPO) can detect abnormal MA in MS. The goal is to determine the effect of DMT efficacy on modulating the extent and clinical/radiological correlates of MA in MS. Thirty [F-18]PBR06 PET scans were performed in 22 MS patients and 8 healthy controls (HC). ‘Glial activity load on PET’ scores, ‘lnGALP’, were compared between MS subjects on DMT with high efficacy versus those on no or lower efficacy treatment and correlated with clinical measures and cortical thickness (CoT). CoGM and WM lnGALP scores were higher in MS vs. HC and were inversely correlated with CoT across groups. In HT-MS group, CoGM and WM lnGALP was significantly lower as compared to LT-MS group but remained abnormally higher than in HC group. Within HT-MS patients, CoGM lnGALP scores were higher in SP vs. RR subgroups, correlated positively with EDSS, T25FW, and fatigue scores, and inversely with CoT. High-efficacy DMTs decrease, but do not normalize, CoGM and WM MA in MS. Such “residual” MA in CoGM is associated with clinical disability, symptom severity and cortical degeneration.
Neuroinflammation in the brain is involved in the development of multiple sclerosis (MS). [F-18]PBR06 positron emission tomography (PET) is a type of imaging that can detect abnormal brain neuroinflammation in MS. The goal of this study is to determine the effect of MS treatment on clinical scores and magnetic resonance imaging (MRI) in MS. Thirty [F-18]PBR06 PET scans were performed in 22 MS patients and 8 healthy controls (HC). The PET scans were compared between MS subjects on high efficacy MS treatment versus those on no or lower efficacy MS treatment and correlated with clinical and MRI measures. High-efficacy DMTs decrease, but do not normalize, neuroinflammation in the brain in MS. Such “residual” brain inflammation is associated with clinical disability, symptom severity and brain degeneration.
